Delivery Order SPE2DB20D2104-SPE2DB25FNBQL
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract valued at $2,392.21. The order carries an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $17,740.52. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 25, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $6,558.15. This is a firm fixed price delivery order with an ultimate completion date of June 20, 2025, and carries no set-aside designation, indicating it was awarded through competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $8,948.63. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is set for ultimate completion by September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a Delivery Order valued at $5,518.26 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 23, 2025, with completion scheduled for September 24, 2025. This firm fixed-price contract represents a non-competitive delivery order placed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for $2,366.60 to supply Xifaxan 550 mg tablets (60-count packages). This is a firm fixed price delivery order with no set-aside designation, executed under open competition. The ultimate completion date is September 24, 2025, with performance to be completed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Xifaxan 550 mg tablets in a quantity of 60 units, with a ceiling value of $16,598.12. This firm fixed-price delivery order is part of a competitive procurement with no set-aside designation and is scheduled for completion by September 10, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order valued at $18,007.34 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed price contract. This non-competitive delivery order, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a routine pharmaceutical procurement executed through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, a major...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNBQLDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 units) with a contract ceiling value of $8,588.18. This competitively awarded, firm fixed price delivery order is scheduled for completion by September 26, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract vehicle with the DLA. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. This delivery order falls under the company's existing $999.999 billion Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026 and provides comprehensive global pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. As a non-set-aside award, this contract demonstrates AmerisourceBergen's capability to compete successfully in federal pharmaceutical procurement across the full spectrum of therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 9/25/25 |